1Elalamy I, Verdy E, Gerotziafas G, et al. Pathogenesis of venous thromboembolic disease in cancer [ J ]. Pathol Biol ( Paris), 2008, 56(4) :184-194.
2Starakis I, Koutras A, Mazokopakis EE. Drug-induced thromboem- bolie events in patients with malignancy [ J ]. Cardiovase Hematol Disord Drug Targets,2010,10 (2) :94-102.
4Goodnough LT, Saito H, Manni A, et al. Increased indicience of thromboembolism in stage 1V breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients [ J ]. Cancer, 1984,54 (7) : 1264-1268.
5Seeho|zer N, Thurlimann B, Koborle D, et al. Combining chemo- therapy and low molecular weight heparin for the treatment of ad- vanced breast cancer: results on clinical response, transferming growth factor beta 1 and fibrin monomer in a phase H study [ J ]. Blood Coagul Fibrinolysis,2007,18(5 ) :415-423.
6Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Petites Cel- lules Group[J]. Cancer,1994,74( 1 ) :38-45.
7Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin,therapy with daheparin, and survival in advanced canc- er: the fragmin advanced malignancy outcome study (FAMOUS) [ J]. J Clin Onco1,2004,22 (10) : 1944-1948.
8Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfa- rin and heparin[ J]. Biomed pharmacother,2004 ,58 :213-219.
